Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could junk food compounds fuel a rising esophagus disease?

NCT ID NCT06093204

Knowledge-focused Sponsor: Federico II University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This study asks whether compounds in ultra-processed foods, like advanced glycation end-products, might play a role in eosinophilic esophagitis, a chronic inflammatory condition of the esophagus. Researchers will compare the diets of 100 people with and without the disease, using food diaries and a skin scanner to measure compound buildup. The goal is to see if these food-derived compounds are more common in patients, which could suggest a dietary link.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dietary evaluation of ultra-processed foods and advanced glycation end-products
What this could lead to
If a link is found, it could point toward dietary changes as a way to manage or prevent eosinophilic esophagitis.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The results may not apply to all ethnic groups, as only Caucasian participants are included.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients both sexes, aged between 3-65 years with diagnosis of eosinophilic esophagitis and age- and sex-matched healthy controls

Ages

3 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * both sexes * age between 3-65 years * sure diagnosis of eosinophilic esophagitis * age- and sex-matched healthy controls * parents/tutor written informed consent. Exclusion Criteria: * lack of written informed consent; * non-Caucasian ethnicity * age at enrollment \< 3 or \>65 years * simultaneous presence of other chronic diseases: eosinophilic gastroenteritis, eosinophilic colitis, achalasia, GERD, hypereosinophilia syndrome, IBD, fungal or viral infections, connective tissue disorders, autoimmune diseases, vasculitis, bullous dermatosis with oesophageal involvement (pemphigus), drug hypersensitivity reactions, drug-induced oesophagitis, graft vs host disease, monogenic disorders (Marfan syndrome type 2, HIES, PTEN). * presence of tattoos, scars, moles or particular lesions on both forearms

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophagitis, eosinophilic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic esophagitis esophagitis, eosinophilic, 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophagitis, eosinophilic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Traslational Medical Science - University of Naples Federico II

    RECRUITING

    Naples, Naples, 80131, Italy

  • Department of Traslational Medical Science - University of Naples Federico II

    RECRUITING

    Naples, Naples, 80131, Italy